Home
Resources
Publications
Sodium Iodide I 123

Sodium Iodide I 123

PMID: 30000618

Abstract:

Information in this record refers to the use of sodium iodide I 123 as a diagnostic agent. Considerable controversy exists in the literature concerning the breastfeeding interruption time after the diagnostic use of sodium iodide I 123, partly depending on assumptions used for the levels of impurities, especially I 125, in commercial products. Some international agencies state that breastfeeding should be interrupted for more than 3 weeks following diagnostic use of sodium iodide I 123.[1][2] This usually will result in permanent discontinuation of breastfeeding for this infant. However, other experts recommend much shorter times. Recent information indicates that I 125 contamination is currently much less than earlier estimates.[3] The American Thyroid Association recommends discontinuation of breastfeeding for only 3 to 4 days after a diagnostic scan[4] and UK authorities recommend a cessation of 42 hours after a 20 MBq dose.[5] The safest course of action may be to have breastmilk tested at a nuclear medicine facility at a hospital. When the radioactivity is at a safe level the mother may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[6] Mothers who receive a dose less than 400 MBq for a thyroid scan need not refrain from close contact with their infants.[7]

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
LS72735	i-Butylammonium iodide			Price
LS72737	i-Propylammonium iodide			Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: